AI Article Synopsis
- The study aims to compare etamsylate and tranexamic acid as methods to reduce blood loss during elective cesarean sections.
- A randomized controlled trial with 180 women showed that both tranexamic acid and etamsylate significantly reduced blood loss compared to a placebo, with lower transfusion needs and better postoperative hemoglobin levels.
- The findings suggest that etamsylate is a safe and effective alternative to tranexamic acid for patients who may have contraindications or higher risk of side effects.
Article Abstract
Objectives: To investigate whether etamsylate may be an alternative to tranexamic acid in reduction of blood loss during elective cesarean section.
Methods: Prospective double-blinded multi-center randomized controlled trial involving 180 qualified women equally divided into three groups each containing 60 women received either tranexamic acid, etamsylate or placebo 20 min before elective cesarean section and blood loss was estimated.
Results: Mean blood loss, cases needing blood transfusion and cases needing further interventions were significantly lower in tranexamic acid and etamsylate group than placebo group, while mean postoperative hemoglobin and hematocrite were significantly higher in both tranexamic acid and etamsylate as compared to placebo.
Conclusions: Etamsylate is an effective second-line therapy (after tranexamic acid) in reducing blood loss during elective cesarean section with low risk of side effects, therefore, it can be an effective alternative to tranexamic acid in cases with contraindications or anticipated to be at high-risk of developing side effects from tranexamic acid.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1515/jpm-2020-0271 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!